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Sir,
Reply to Chhablani
We thank Dr Chhablani1 for his interest in our article2;
we evaluated diffuse diabetic macular oedema and
obtained good functional and anatomic results during
a follow-up of 12 months after treatment with intra-
vitreal bevacizumab, when compared with the
combination of intravitreal triamcinolone and laser
photocoagulation. We agree that intravitreal
bevacizumab lacks in large randomized controlled
trials and could be used in case of gross macular oedema
in order to reduce macular thickening, followed by
laser photocoagulation.
The latter remains indeed the gold standard for diabetic
macular oedema.
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